{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=22",
    "query": {
      "condition": "Carcinoma, Non Small Cell Lung",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 3680,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T19:45:44.165Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01523587",
      "title": "LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "afatinib",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 795,
      "start_date": "2012-03-05",
      "completion_date": "2017-12-27",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 33,
      "location_summary": "Chandler, Arizona • La Jolla, California • Sacramento, California + 27 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523587"
    },
    {
      "nct_id": "NCT00525148",
      "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 129,
      "start_date": "2007-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525148"
    },
    {
      "nct_id": "NCT06566443",
      "title": "Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Honokiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2025-02-13",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06566443"
    },
    {
      "nct_id": "NCT05219734",
      "title": "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Personalized Cancer Monitoring (PCM)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Invitae Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2021-11-29",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 2,
      "location_summary": "Columbus, Indiana • Jacksonville, North Carolina",
      "locations": [
        {
          "city": "Columbus",
          "state": "Indiana"
        },
        {
          "city": "Jacksonville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05219734"
    },
    {
      "nct_id": "NCT04450732",
      "title": "Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Biliary Tract Cancer",
        "HER2-Positive Salivary Gland Carcinomas",
        "HER2-Positive Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "GQ1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GeneQuantum Healthcare (Suzhou) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2020-07-07",
      "completion_date": "2024-05-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04450732"
    },
    {
      "nct_id": "NCT03418532",
      "title": "MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR-mutated NSCLC (Disorder)"
      ],
      "interventions": [
        {
          "name": "MP0250 DARPin® drug candidate, Osimertinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-22",
      "completion_date": "2020-04-24",
      "has_results": false,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03418532"
    },
    {
      "nct_id": "NCT00698516",
      "title": "Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Small-cell Lung Cancer (SCLC)",
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-07",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-03-27",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 16,
      "location_summary": "Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698516"
    },
    {
      "nct_id": "NCT00923481",
      "title": "A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Pheochromocytoma",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Fostamatinib disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2009-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-09-30",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923481"
    },
    {
      "nct_id": "NCT00379132",
      "title": "131-I-TM-601 Study in Adults With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Melanoma",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Prostate Adenocarcinoma",
        "Glioma",
        "Primary Solid Tumors"
      ],
      "interventions": [
        {
          "name": "131-I-TM-601 (chlorotoxin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransMolecular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-08",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2009-03-31",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379132"
    },
    {
      "nct_id": "NCT07938463",
      "title": "Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALK Positive Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "TNG462 vopimetostat",
          "type": "DRUG"
        },
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2027-04-30",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T19:45:44.165Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07938463"
    }
  ]
}